Chardan Capital Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR)

Key Points

• Chardan Capital reaffirmed a Buy rating on Monopar with a $100 price target, implying roughly an 84.84% upside from the prior close.
• Market consensus remains an average Buy with an average price target of $107, though analyst views vary (Morgan Stanley at overweight/$115, while Weiss and Wall Street Zen issued sell calls); MNPR opened at $54.10 and trades in a 52‑week range of $26.06–$105.00.
• Several institutional investors — including Wellington Management, RA Capital, Deerfield, Siren and TCG — have recently built or increased positions in Monopar, signaling notable institutional interest.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Chardan Capital in a research note issued on Monday,Benzinga reports. They currently have a $100.00 price target on the stock. Chardan Capital's target price suggests a potential upside of 84.84% from the stock's previous close.

Several other analysts have also recently commented on MNPR. Morgan Stanley initiated coverage on shares of Monopar Therapeutics in a report on Friday, January 9th. They set an "overweight" rating and a $115.00 price target for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Monopar Therapeutics in a research note on Thursday, January 22nd. BTIG Research restated a "buy" rating and set a $104.00 price target on shares of Monopar Therapeutics in a report on Monday, February 23rd. Wall Street Zen lowered Monopar Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, January 10th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $107.00.

Monopar Therapeutics Price Performance

MNPR stock opened at $54.10 on Monday. Monopar Therapeutics has a 52-week low of $26.06 and a 52-week high of $105.00. The company's 50 day simple moving average is $59.62 and its 200-day simple moving average is $70.95. The firm has a market capitalization of $361.55 million, a P/E ratio of -29.73 and a beta of 1.58.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings data on Friday, March 27th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.10). Sell-side analysts predict that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Trading of Monopar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP bought a new stake in Monopar Therapeutics in the third quarter valued at $18,904,000. Siren L.L.C. bought a new position in shares of Monopar Therapeutics during the fourth quarter valued at $13,863,000. Deerfield Management Company L.P. acquired a new stake in shares of Monopar Therapeutics in the 3rd quarter valued at $13,048,000. RA Capital Management L.P. boosted its stake in shares of Monopar Therapeutics by 30.5% in the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company's stock valued at $43,569,000 after purchasing an additional 156,000 shares in the last quarter. Finally, TCG Crossover Management LLC bought a new stake in shares of Monopar Therapeutics in the 3rd quarter worth about $12,496,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.